covid 19 respiratory infection
COVID-19 trials proliferated rapidly during the pandemic and now encompass antiviral treatments, long COVID management, and ongoing vaccine refinements for new variants. The platform trial model β€” where multiple interventions share a single control arm β€” was pioneered at scale for COVID-19 (RECOVERY, ACTIV-3, SOLIDARITY) and has since been adopted across other disease areas.
Active trials address long COVID (fatigue, cognitive impairment, autonomic dysfunction), antiviral combinations for high-risk outpatients, mucosal vaccines for variant-resistant immunity, and mechanistic studies into post-COVID organ damage. Paxlovid rebound, nirmatrelvir resistance, and immunocompromised host management are current investigation areas.
Disease Burden & Epidemiology
COVID-19, caused by SARS-CoV-2, has infected an estimated 771 million people globally and is associated with at least 7 million confirmed deaths as of mid-2024 — though excess mortality analyses suggest total pandemic-attributable deaths may exceed 15–20 million. In the United States, the CDC confirmed approximately 103 million cases and 1.2 million deaths through 2023. Clinical trial activity around COVID-19 was unprecedented: over 10,000 COVID-19 trials were registered on ClinicalTrials.gov during the pandemic, more than any other single condition in history. While acute hospitalized COVID-19 is no longer the primary driver of current trial activity, two major research domains remain active: treatment and prevention of COVID-19 in immunocompromised populations (transplant recipients, cancer patients, those on immunosuppressants) who remain at high risk for severe disease, and long COVID — formally designated post-acute sequelae of SARS-CoV-2 (PASC). An estimated 5–10% of people infected with SARS-CoV-2 develop long COVID, creating a global burden of tens of millions of patients experiencing persistent fatigue, cognitive impairment, dyspnea, autonomic dysfunction, and other symptoms lasting months to years.
Key Research Trends & Landmark Studies
The RECOVERY trial, enrolling over 47,000 participants across multiple countries, established dexamethasone as the first life-saving treatment for severe COVID-19, baricitinib as an effective anti-inflammatory in hospitalized patients, and definitively ruled out hydroxychloroquine β€” among the most influential adaptive platform trials in modern medicine. The EPIC-HR trial established nirmatrelvir/ritonavir (Paxlovid) as reducing hospitalization by 89% in high-risk outpatients within 5 days of symptom onset. The PANORAMIC UK trial showed Paxlovid reduced symptom duration by approximately 1 day in vaccinated community patients β€” a more modest benefit highlighting the importance of patient selection. For long COVID, the NIH RECOVER platform is the largest ongoing investigation, with multiple nested intervention trials; the RECOVER-VITAL trial evaluating extended nirmatrelvir in long COVID is actively enrolling. Vaccine platform trials including MOSAIC (pan-coronavirus), mRNA-based mucosal vaccine programs, and population-based effectiveness studies of XBB.1.5 and JN.1-adapted bivalent vaccines represent the ongoing prevention research portfolio.
Patient Guide: How to Find & Join a Trial
Current COVID-19 clinical trial enrollment falls into three broad categories. For immunocompromised patients: trials evaluating optimized vaccination strategies, pre-exposure prophylaxis with monoclonal antibodies or antivirals, and treatment escalation protocols are actively recruiting at transplant centers, oncology programs, and infectious disease clinics. For long COVID: adults who experienced SARS-CoV-2 infection (confirmed by PCR or antigen test) and have had persistent symptoms for more than 12 weeks may be eligible for RECOVER platform trials and other intervention studies; no specific prior COVID-19 severity is required. For vaccine research: healthy adults and older adults remain eligible for immunogenicity studies evaluating next-generation mucosal and variant-adapted COVID-19 vaccines, typically conducted at vaccine research centers at universities and health departments. The RECOVER trial finder (recovercovidtrial.net) and ClinicalTrials.gov's COVID-19 condition filter are the most reliable resources for current enrollment opportunities.